Kevin Brosseau, Canada's fentanyl czar, travelled to Washington on June 15 to present new data on declining opioid-related deaths to U.S. Attorney General Pamela Bondi, according to The Globe and Mail.

The meeting — which also included Minister of Justice and Attorney General Sean Fraser and Minister of Public Safety Gary Anandasangaree, per the Government of Canada — put Canadian officials across the table from the senior U.S. law-enforcement official most directly responsible for federal narcotics policy.

The headline figure Brosseau carried south was an aggregate: 6,161 opioid-related deaths in Canada between July 2024 and June 2025, averaging 17 per day. That number is still staggering in absolute terms, but it sits within a trend line that moved in the right direction: Canada recorded a measurable decline in opioid-related deaths in 2024 compared to 2023, the first such drop in recent years. The vast majority of apparent opioid toxicity deaths remain accidental rather than intentional, a distinction that matters for how prevention resources are targeted.

The Role and Its Origins

Brosseau, a former RCMP officer, was appointed to the role in early 2025 in circumstances shaped as much by Washington's trade posture as by domestic public-health imperatives. The position emerged from talks between Prime Minister Justin Trudeau and President Donald Trump in which tariffs and border enforcement were bundled into the same negotiating frame. Trump had framed planned tariffs on Canada, Mexico and China partly as leverage to curb illicit fentanyl flows into the United States; Ottawa's appointment of a named, accountable point person was a concrete signal that Canada was taking the file seriously on American terms.

The "czar" framing is worth noting. It is borrowed wholesale from U.S. political vocabulary — drug czar, border czar — and its adoption reflects the extent to which Canada's positioning on this file has been calibrated for an American audience. Brosseau's mandate is nominally domestic, focused on co-ordinating federal efforts to reduce opioid harm, but his most visible activity since appointment has involved cross-border diplomacy rather than, say, convening provincial health ministers.

What the Numbers Mean for the Bilateral File

The data Brosseau presented to Bondi serves a specific diplomatic purpose. The Trump administration's case for tariff pressure rested in part on the claim that Canada was not doing enough to interdict fentanyl precursors and finished product crossing the border. Canadian officials have consistently pushed back on the scale of that flow — the volume of fentanyl entering the U.S. from Canada is a fraction of what crosses from Mexico — but data showing a domestic death decline gives Brosseau something tangible to put on the table: evidence of operational progress, not just jurisdictional argument.

Whether that evidence shifts Bondi's or the administration's posture is a separate question. The U.S. political incentive structure on fentanyl is not primarily about Canadian import volumes; it is about domestic accountability. Ottawa's interest is in keeping the bilateral relationship from being further complicated by a file that, statistically, Canada did not create and cannot fully control.

The June 15 meeting is the most recent in a sequence of high-level engagements on this file since Brosseau's appointment in February 2025. That the czar is still making the Washington circuit more than a year into the role, and now with updated mortality data in hand, suggests the file remains actively managed at the political level on both sides of the border — not a settled matter, but not one that has been quietly shelved either.